Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82,484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis.
Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L, Bishop J, Nagle S, Stephens DM, Jaglowski S, Hill B, Danilov AV. Kittai AS, et al. Among authors: huang y. Transplant Cell Ther. 2021 Jan;27(1):46-52. doi: 10.1016/j.bbmt.2020.09.028. Epub 2020 Sep 29. Transplant Cell Ther. 2021. PMID: 33002640 Free article.
Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
Sigmund AM, Denlinger N, Huang Y, Bond D, Voorhees T, Bajwa A, Elder P, Brammer JE, Saad A, Penza S, Vasu S, de Lima M, Jaglowski S, Kittai AS. Sigmund AM, et al. Among authors: huang y. Transplant Cell Ther. 2022 Jun;28(6):342.e1-342.e5. doi: 10.1016/j.jtct.2022.02.021. Epub 2022 Mar 4. Transplant Cell Ther. 2022. PMID: 35248778 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 36164094
Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience.
Schaefer A, Huang Y, Kittai A, Maakaron JE, Saygin C, Brammer J, Penza S, Saad A, Jaglowski SM, William BM. Schaefer A, et al. Among authors: huang y. Cancer Manag Res. 2021 Nov 30;13:8901-8906. doi: 10.2147/CMAR.S321202. eCollection 2021. Cancer Manag Res. 2021. PMID: 34876852 Free PMC article.
Fluoroquinolone Prophylaxis in Autologous Stem Cell Transplantation: Worthy of a Second Look.
Maakaron JE, Liscynesky C, Boghdadly ZE, Huang Y, Agyeman A, Brammer J, Penza S, Efebera Y, Benson D, Rosko A, William B, Jaglowski SM. Maakaron JE, et al. Among authors: huang y. Biol Blood Marrow Transplant. 2020 Aug;26(8):e198-e201. doi: 10.1016/j.bbmt.2020.03.027. Epub 2020 Apr 15. Biol Blood Marrow Transplant. 2020. PMID: 32304873 Free article.
Second cancer incidence in CLL patients receiving BTK inhibitors.
Bond DA, Huang Y, Fisher JL, Ruppert AS, Owen DH, Bertino EM, Rogers KA, Bhat SA, Grever MR, Jaglowski SM, Maddocks KJ, Byrd JC, Woyach JA. Bond DA, et al. Among authors: huang y. Leukemia. 2020 Dec;34(12):3197-3205. doi: 10.1038/s41375-020-0987-6. Epub 2020 Jul 23. Leukemia. 2020. PMID: 32704159 Free PMC article.
82,484 results
You have reached the last available page of results. Please see the User Guide for more information.